Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27566889 | 0.89 | DGAT1 (0.40) | BTKGRM2DGAT1HPGDCHRM2 | |
| Hydrochloric Acid SCHEMBL6600019 | 0.87 | DGAT1 (0.39) | BTKGRM2DGAT1HPGDCHRM2 | |
| SCHEMBL6597535 | 0.82 | DGAT1 (0.42) | BTKDGAT1HPGDCHRM2CHRM1 | |
| SCHEMBL27950403 | 0.80 | GAA (0.41) | BTKDGAT1HPGDCHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL2941903 | 0.74 | LMNA (0.43) | BTKKMT2ALMNAPLGPLAT | |
| SCHEMBL5264559 | 0.74 | HRH3 (0.46) | BTKKMT2AHSD17B10LMNAPLG | |
| SCHEMBL1072603 | 0.74 | HRH3 (0.46) | BTKKMT2AHSD17B10LMNAPLG | |
| SCHEMBL10328238 | 0.74 | HRH3 (0.46) | BTKKMT2AHSD17B10LMNAPLG | |
| SCHEMBL20775447 | 0.73 | DGAT1 (0.36) | BTKGRM2DGAT1CHRM2CHRM1 | |
| SCHEMBL30984403 | 0.73 | DGAT1 (0.36) | BTKGRM2DGAT1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3600451-B1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2024-12-12 | — | — | US | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MINERVA BIOTECHNOLOGIES CORPORATION | 2021-09-30 | — | — | US | disclosed |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MCL1, CD44, EPCAM | BTK 4765/4885KMT2A 1059/4885HSD17B10 4001/4885 |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MCL1, CD44, CRABP2 | BTK 4859/4885KMT2A 2022/4885HSD17B10 4083/4885 |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | BTK 4859/4885KMT2A 2022/4885HSD17B10 4083/4885 |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MCL1, POU2F1, NES | BTK 4615/4885KMT2A 1674/4885HSD17B10 3082/4885 |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | BTK 4859/4885KMT2A 2022/4885HSD17B10 4083/4885 |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | BTK 4859/4885KMT2A 2022/4885HSD17B10 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.